Consensus AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
76.9 ^USD	-0.18%		-0.36%	+14.18%

May. 17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE
May. 16	AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial	MT

Evolution of the average Target Price on AstraZeneca PLC

Price target over the last 5 years

History of analyst recommendation changes

7c79708e9d6ac0e67f4a0c4a2af9.e9YBToXrxwySUOKjjWwBFGjUHc1XyHSW24ESu-DTEUI.P5V1ALXZkXbiGa3n5C94dQrmQrhggC3houpdjomwa3pDr0si5r6LR8hghQ~20daefe9a5b1303065454d3192c26278

Analyst Recommendations on AstraZeneca PLC

ASTRAZENECA : UBS reiterates its Sell rating	May. 15	ZD
ASTRAZENECA : Buy rating from JP Morgan	May. 14	ZD
Jefferies Lifts AstraZeneca PT, Maintains Hold Rating	May. 08	MT
ASTRAZENECA : Jefferies sticks Neutral	May. 08	ZD
UBS raises Centrica to 'buy' from 'neutral	May. 08	AN
Berenberg Raises AstraZeneca PT, Keeps Rating at Buy	May. 07	MT
ASTRAZENECA : Berenberg keeps its Buy rating	May. 07	ZD
AstraZeneca target raised; Antofagasta lowered	May. 07	AN
ASTRAZENECA : Deutsche Bank gives a Neutral rating	Apr. 30	ZD
ASTRAZENECA : JP Morgan maintains a Buy rating	Apr. 29	ZD
Deutsche Bank likes Frasers; Barclays cuts JD	Apr. 29	AN
ASTRAZENECA : DZ Bank sticks Neutral	Apr. 26	ZD
ASTRAZENECA : UBS keeps a Sell rating	Apr. 26	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	Apr. 26	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	Apr. 26	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	Apr. 26	MT
Peel Hunt cuts ConvaTec to 'reduce'	Apr. 26	AN
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade	Apr. 25
ASTRAZENECA : UBS maintains a Sell rating	Apr. 25	ZD
ASTRAZENECA : Jefferies sticks Neutral	Apr. 25	ZD
ASTRAZENECA : JP Morgan remains its Buy rating	Apr. 25	ZD
ANALYST RECOMMENDATIONS : Meta Platforms, UPS, Boeing, Chipotle, Dell Technologies...	Apr. 25
ASTRAZENECA : Bernstein reiterates its Buy rating	Apr. 24	ZD
ASTRAZENECA : JP Morgan reaffirms its Buy rating	Apr. 23	ZD
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

153.9 USD

Average target price

167.7 USD

Spread / Average Target

+9.02%

High Price Target

220.2 USD

Spread / Highest target

+43.10%

Low Price Target

131.3 USD

Spread / Lowest Target

-14.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering AstraZeneca PLC

UBS	Matthew Weston
JPMORGAN	James Gordon
Jefferies & Co.
JEFFERIES	Peter Welford
BERENBERG	Luisa Hector
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
Barclays
DZ BANK	Elmar Kraus
alphavalue	Abhishek Raval
BERNSTEIN RESEARCH	Justin Smith
Deutsche Bank Securities
Bernstein
B. Riley
RBC Capital Markets
Berenberg Bank
BMO Capital
Stifel Nicolaus
CREDIT SUISSE	Dominic Lunn
HSBC
Argus
Morgan Stanley
GOLDMAN SACHS	Keyur Parekh
Bank of America Securities/Merrill Lynch
Danske Bank Group
Kepler Capital Markets
Kepler Cheuvreux
DEUTSCHE BANK	Emmanuel Papadakis
SVB Leerink
Bryan, Garnier & Co.
Societe Generale
Liberum Capital
ODDO BHF
BANK OF AMERICA (BOFA)	Sachin Jain

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar